Significance of interleukin-33 and its related cytokines in patients with breast cancers

Frontiers in Immunology

Volumn 5, Issue APR, 2014, Pages

  Liu, Jing ^a   Shen, Jia Xin ^a,b   Hu, Jia Lin ^a,b   Huang, Wen He ^b   Zhang, Guo Jun ^b  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Breast cancer; Cytokines; Immunosuppression; Interleukin 33; ST2 ST2L

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 33; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 84900846603     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00141     Document Type: Article

References (27)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin (2013) 63(1):11-30. doi:10.3322/caac.21166.
2. Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol Cell endocrinol (2014) 382(1):673-82. doi:10.1016/j.mce.2013.06.003.
3. Mattii M, Ayala F, Balato N, Filotico R, Lembo S, Schiattarella M, et al. The balance between pro- and anti-inflammatory cytokines is crucial in human allergic contact dermatitis pathogenesis: the role of IL-1 family members. Exp Dermatol (2013) 22(12):813-9. doi:10.1111/exd.12272.
4. Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun (2009) 384(1):105-9. doi:10.1016/j.bbrc.2009.04.081.
5. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol (2010) 10(2):103-10. doi:10.1038/nri2692.
6. Hong YS, Moon SJ, Joo YB, Jeon CH, Cho ML, Ju JH, et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci (2011) 26(9):1132-9. doi:10.3346/jkms.2011.26.9.1132.
7. Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med (2013) 210(13):2939-50. doi:10.1084/jem.20130351.
8. Volarevic V, Mitrovic M, Milovanovic M, Zelen I, Nikolic I, Mitrovic S, et al. Protective role of IL-33/ST2 axis in Con A-induced hepatitis. J Hepatol (2012) 56(1):26-33. doi:10.1016/j.jhep.2011.03.022.
9. Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol (2013) 6(3):311-8.
10. Hu LA, Fu Y, Zhang DN, Zhang J. Serum IL-33 as a diagnostic and prognostic marker in non-small cell lung cancer. Asian Pac J Cancer Prev (2013) 14(4):2563-6. doi:10.7314/APJCP.2013.14.4.2563.
11. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer (2013) 134(7):1669-82. doi:10.1002/ijc.28481.
12. +) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett (2013) 335(2):463-71. doi:10.1016/j.canlet.2013.03.002.
13. Deutsch E. Medical experimentation: international rules and practice. Law Rev (1989) 19:1-10.
14. Bernhard OK, Mathias RA, Barnes TW, Simpson RJ. A fluorescent microsphere-based method for assay of multiple analytes in plasma. Methods Mol Biol (2011) 728:195-206. doi:10.1007/978-1-61779-068-3_12.
15. Liu J, Wei XL, Huang WH, Chen CF, Bai JW, Zhang GJ. Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas. PLoS One (2012) 7(12):e52675. doi:10.1371/journal.pone.0052675.
16. Jorns JM, Healy P, Zhao L. Review of estrogen receptor, progesterone receptor, and HER-2/neu immunohistochemistry impacts on treatment for a small subset of breast cancer patients transferring care to another institution. Arch Pathol Lab Med (2013) 137(11):1660-3. doi:10.5858/arpa.2012-0670-OA.
17. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancerregistry. Breast Cancer Res Treat (2013) 139(2):539-52. doi:10.1007/s10549-013-2560-8.
18. Lopetuso LR, Scaldaferri F, Pizarro TT. Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair (2012) 5(1):18. doi:10.1186/1755-1536-5-18.
19. Kamijo S, Takeda H, Tokura T, Suzuki M, Inui K, Hara M. IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation. J Immunol (2013) 190(9):4489-99. doi:10.4049/jimmunol.1201212.
20. Ciccia F, Alessandro R, Rizzo A, Raimondo S, Giardina A, Raiata F, et al. IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. Ann Rheum Dis (2013) 72(2):258-64. doi:10.1136/annrheumdis-2012-201309.
21. Dong R, Dong K, Wang X, Chen G, Shen C, Zheng S. Interleukin-33 overexpression is associated with gamma-glutamyl transferase in biliary atresia. Cytokine (2013) 61(2):433-7. doi:10.1016/j.cyto.2012.10.035.
22. Byers DE, Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X, et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest (2013) 123(12):5410. doi:10.1172/JCI65570.
23. Gillibert-Duplantier J, Duthey B, Sisirak V, Salaun D, Gargi T, Tredan O, et al. Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Oncogene (2012) 31(30):3516-24. doi:10.1038/onc.2011.525.
24. Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN, Arsenijevic N, et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol (2011) 41(7):1902-12. doi:10.1002/eji.201141417.
25. Brown JR, Digiovanna MP, Killelea B, Lannin DR, Rimm DL. Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer. Lab Invest (2014) 94(1):98-106. doi:10.1038/labinvest.2013.128.
26. Chen SF, Nieh S, Jao SW, Wu MZ, Liu CL, Chang YC, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol (2013) 231(2):180-9. doi:10.1002/path.4226.
27. Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, et al. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep (2013) 3:3456. doi:10.1038/srep03456.